DEADLINE NEXT WEEK: Berger Montague Advises Integer Holdings Corporation (NYSE: ITGR) Investors to Contact the Firm Before February 9, 2026
globenewswire.com
Want to monitor URGN?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor URGNurogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.